…genetics, and personal health history play a significant role. Women with a family history of ovarian, breast, uterine, or colorectal cancer may have inherited gene mutations like BRCA1 and BRCA2,…
…United Kingdom, presented “Rucaparib vs chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: efficacy and safety from ARIEL4, a randomized phase 3 study.” Watch “Rucaparib vs….
…and ovarian cancer While having a BRCA1 or BRCA2 mutation puts women at high risk of developing breast or ovarian cancer, not all women with the mutation end up developing…
…a breast cancer family history clinic found that women with a BRCA2 mutation had a 17-times higher risk of developing ovarian cancer than average, and women with a BRCA1 mutation…
…on August 7th. Much like the BRCA1 and BRCA2 mutations, which were discovered in the 1990s and which also increase a woman’s risk for ovarian cancer, those who carry this…
…opt for testing to determine whether they carry genetic mutations such as BRCA1, BRCA2 and Lynch syndrome—all of which increase the risk of ovarian cancer. Women who know they have…
…patients. It has been suggested that EMSY amplification may cause suppression on DNA damage repair in a similar manner as in BRCA1 and BRCA2 ovarian cancer patients. Researchers from both…
In the late 1990s, Sue Friedman was diagnosed with breast cancer. She learned that she carried a mutation in the BRCA gene that made her more likely to develop both…
…with ovarian cancer, a doctor may test for predictive biomarkers, such as BRCA and other cancer-causing gene mutations. Detected through blood or saliva tests, these mutations can signal to a…
…are known to be highly effective in BRCA positive women. Yet, especially striking are the results in women who do not have a BRCA mutation – they had an increase…
…olaparib. BRCA positive patients had only a slight increase in PFS (19.4 vs. 16.5 months), which is to be expected since PARP inhibitors are known to be highly effective in BRCA positive women. Yet,…
Lindsay Avner founded Bright Pink in 2007, shortly after she learned that she carried a mutation in the BRCA gene. Just 22 years old when she was tested, Lindsay realized…
Get email updates about research news, action alerts, and ways to join the fight.
